GS
ATNM icon

Gagnon Securities’s Actinium Pharmaceuticals ATNM Stock Holding History

Gagnon Securities’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178K Sell
182,142
-19,158
-10% -$22.1K 0.03% 81
2026
Q1 		$200K Sell
201,300
-507
-0.3% -$603 0.05% 82
2025
Q4 		$274K Sell
201,807
-24,450
-11% -$35.7K 0.06% 77
2025
Q3 		$362K Sell
226,257
-365
-0.2% -$595 0.07% 71
2025
Q2 		$317K Hold
226,622
– – 0.06% 70
2025
Q1 		$365K Buy
+226,622
New +$288K 0.08% 70

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Gagnon Securities's ATNM Position: Q2 2026 in Review

Gagnon Securities reduced its Actinium Pharmaceuticals (ATNM) stake by 9.5% in Q2 2026, selling an estimated $22.1K and leaving 182,142 shares worth $178K. The position accounts for 0.03% of the portfolio, ranked #81.

Gagnon Securities first reported a position in ATNM in Q1 2025 and has held it in 6 quarters since. The position peaked at $365K in Q1 2025. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Gagnon Securities held 182,142 shares of Actinium Pharmaceuticals worth $178K as of Q2 2026.
  • Gagnon Securities sold 19,158 Actinium Pharmaceuticals shares in Q2 2026, an estimated $22.1K.
  • Actinium Pharmaceuticals made up 0.03% of Gagnon Securities's portfolio in Q2 2026, its #81 holding.
  • Gagnon Securities first reported a position in Actinium Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Gagnon Securities's Actinium Pharmaceuticals position peaked at $365K in Q1 2025.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Gagnon Securities's 13F filing for Q2 2026, filed 5 Aug 2026.